This inventor holds 3 USPTO granted patents. Top assignee: The Biomembrane Institute. Active years: 1993-1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1993-1998
Title: Helio K Takahashi: Innovator in Monoclonal Antibodies and Vaccine Development
Introduction
Helio K Takahashi is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies and vaccines aimed at combating cancer. With a total of 3 patents to his name, Takahashi's work is at the forefront of innovative cancer therapies.
Latest Patents
Takahashi's latest patents focus on monoclonal antibodies and vaccine development directed towards human cancer cells. One of his notable inventions is a method for producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens. This method involves immunizing a host, fusing splenocytes with myeloma cells, and culturing hybridoma cells to select those that secrete the desired antibodies. Additionally, he has developed a vaccine designed to prevent the growth and replication of cancer cells expressing mucin-type glycoproteins. This vaccine comprises a purified mucin-type glycoprotein or a chemically synthesized carbohydrate determinant conjugated to a carrier peptide, along with a pharmaceutically acceptable carrier.
Career Highlights
Helio K Takahashi is currently associated with The Biomembrane Institute, where he continues to advance his research in immunology and cancer treatment. His innovative approaches have the potential to significantly impact the field of cancer therapy, providing new avenues for treatment and prevention.
Collaborations
Takahashi has collaborated with notable colleagues, including Thomas J Kjeldsen and Henrik Clausen. These partnerships have fostered a collaborative environment that enhances the research and development of effective cancer therapies.
Conclusion
Helio K Takahashi's contributions to the field of monoclonal antibodies and vaccine development are noteworthy. His innovative methods and dedication to cancer research position him as a key figure in the ongoing fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile